Using Virtual Reality (VR) Models for Robotic Prostatectomy - UNC
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT03870269 |
|
Recruitment Status :
Enrolling by invitation
First Posted : March 12, 2019
Last Update Posted : February 10, 2021
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Prostate Cancer | Device: Ceevra Reveal | Not Applicable |
| Study Type : | Interventional (Clinical Trial) |
| Estimated Enrollment : | 40 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Masking: | Single (Participant) |
| Primary Purpose: | Treatment |
| Official Title: | Using Virtual Reality (VR) Models for Robotic Prostatectomy - UNC |
| Actual Study Start Date : | February 25, 2019 |
| Estimated Primary Completion Date : | June 30, 2021 |
| Estimated Study Completion Date : | June 30, 2022 |
| Arm | Intervention/treatment |
|---|---|
|
Experimental: Intervention Arm
Subjects whose surgeon will be viewing VR models in addition to the source CT/MR image in connection with the case.
|
Device: Ceevra Reveal
VR models generated using Ceevra Reveal are viewed by surgeons in connection with the case in addition to source CT/MR image. |
|
No Intervention: Control Arm
Subjects whose surgeon will only be viewing CT/MR images in connection with the case.
|
- Total operative time [ Time Frame: During procedure, not to exceed 12 hours ]
- Blood loss (measured in cubic centimeters) [ Time Frame: Measured at end of procedure, not to exceed 12 hours ]
- Intraoperative conversion from robotic assisted laparoscopic procedure to open procedure [ Time Frame: During procedure, not to exceed 12 hours ]
- Intraoperative complication [ Time Frame: During procedure, not to exceed 12 hours ]
- Patient hospital stay [ Time Frame: Measured at time of patient discharge, up to 10 days ]
- Positive tumor margin (assessed via standard post-operative biopsy) [ Time Frame: Measured 1-2 weeks after discharge ]
- Postoperative Gleason Score [ Time Frame: Measured up to 3 months after discharge ]
- Postoperative oncologic stage (T stage) [ Time Frame: Measured up to 3 months after discharge ]
- Readmission [ Time Frame: Measured up to 6 months after discharge ]
- Postoperative prostate-specific antigen (PSA) [ Time Frame: Measured up to 12 months after disccharge ]
- Postoperative erectile function [ Time Frame: Measured via survey up to 18 months after discharge ]
- Postoperative continence [ Time Frame: Measured via survey up to 18 months after discharge ]
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
| Sexes Eligible for Study: | Male |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Patient is undergoing robotic prostatectomy being performed by participating surgeon
- Patient is willing to be randomized between intervention and control arms
Exclusion Criteria:
- Patients with prior pelvic radiation
- Patients with prior androgen deprivation therapy
- Patients with prior localized ablative therapy
- Patients with prior TURP or other surgical BPH treatment
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03870269
| United States, North Carolina | |
| UNC Hospital | |
| Chapel Hill, North Carolina, United States, 27514 | |
| Principal Investigator: | Eric Wallen, MD | University of North Carolina, Chapel Hill |
| Responsible Party: | Ceevra, Inc. |
| ClinicalTrials.gov Identifier: | NCT03870269 |
| Other Study ID Numbers: |
17-0904RP |
| First Posted: | March 12, 2019 Key Record Dates |
| Last Update Posted: | February 10, 2021 |
| Last Verified: | February 2021 |
| Individual Participant Data (IPD) Sharing Statement: | |
| Plan to Share IPD: | Undecided |
| Studies a U.S. FDA-regulated Drug Product: | No |
| Studies a U.S. FDA-regulated Device Product: | Yes |
|
Prostatic Neoplasms Genital Neoplasms, Male Urogenital Neoplasms |
Neoplasms by Site Neoplasms Prostatic Diseases |

